On December 4, 2024, a highly anticipated mRNA technology patent ownership dispute case was heard in the First Court of the Supreme People's Court. Tao Kaiyuan, the vice president of the Supreme People's Court and the second level judge, served as the presiding judge of the case. Some deputies to the National People's Congress, members of the National Committee of the Chinese People's Political Consultative Conference, representatives of intellectual property scholars, representatives of scientific researchers, several news media and the public attended the trial. One of the mRNA patents involved in this case is represented by ZYIP.

Since its establishment, ZYIP has always adhered to quality first and focused on providing high-quality intellectual property agency services. Among the numerous patents represented by ZYIP, hundreds of them have been applied in legal affairs such as invalidation, infringement litigation, and rights protection, effectively safeguarding the legitimate rights and interests of customers and highlighting the strong defense of these patents at the legal level. At the same time, thousands of patents have been granted through cross licensing, greatly promoting technology exchange and sharing, and facilitating the collaborative development of the industry.